Manipal Health Enterprises Limited operates India's largest multispecialty healthcare delivery network by bed capacity. The core value proposition revolves around delivering a comprehensive range of patient-centric care services, spanning outpatient consultations to advanced inpatient care, diagnostics, and pharmacy services. The underlying business model relies on protocol-driven care backed by advanced infrastructure, with a distinct focus on tertiary and quaternary care (CONGO-R: cardiac sciences, oncology, neurosciences, gastro sciences, orthopedics, and renal sciences), which accounted for 64.30% of their gross inpatient revenues in Fiscal 2026. Alongside organic growth, the company employs a highly repeatable playbook for integrating transformative acquisitions, successfully onboarding major regional networks like AMRI, Medica Synergie, and the Sahyadri Group into its ecosystem to rapidly scale operations. The company caters to a highly diversified patient demographic, drawing footfalls from extensive domestic catchments as well as international markets such as Nepal, Bangladesh, Sri Lanka, the Middle East, and Africa. To mitigate financial concentration risks, its revenue is well-distributed among various payor segments. In Fiscal 2026, direct "Cash" payments by domestic patients accounted for 30.33% of gross inpatient revenues, while Third-Party Administrators (TPA) and Insurance contributed the dominant share at 49.51%, and government-sponsored schemes contributed 14.03%. Geographically, the enterprise maintains a robust pan-India presence and is uniquely positioned as the only private hospital chain with leadership in three major metropolitan hubs: Bengaluru, Kolkata, and Pune. Being a healthcare service provider, the company does not operate traditional manufacturing plants; instead, its physical infrastructure and capacity are measured by its vast hospital network and bed count. As of March 31, 2026, the company operated a massive network of 49 hospitals equipped with 13,037 licensed beds. The network infrastructure is strategically split into 29 owned hospitals (6,099 beds) and 20 managed O&M hospitals (6,938 beds) spanning key regions like Karnataka, Maharashtra, West Bengal, and beyond. Operationally, the company demonstrates high capacity utilization, recording a healthy bed occupancy rate of 64.47% in FY26. The network successfully treated 0.53 million inpatient footfalls and 5.48 million outpatient footfalls during the same period. Operationally, the company places a significant emphasis on continuous medical innovation and the adoption of cutting-edge clinical technologies. The facilities routinely perform highly complex interventions, boasting one of the highest reported volumes of robotic-assisted spine surgeries in India. A critical R&D and operational milestone includes pioneering Asia's first post-mortem organ revival using extracorporeal membrane oxygenation at its Dwarka facility, enabling successful multi-organ retrieval. To optimize operational efficiency despite the rising volume of complex CONGO-R cases, the company successfully reduced its Average Length of Stay (ALOS) to 2.78 days in FY26, ensuring higher patient throughput and maximum asset utilization. As per financial performance, Manipal Health Enterprises Limited has posted total income / net profits of Rs 6,265.17 Cr / Rs 533.20 Cr (FY24), Rs 8,362.79 Cr / Rs 1,081.67 Cr (FY25) and Rs 10,520.52 Cr / Rs 916.52 Cr (FY26). So as per previous financials data, the company has shown phenomenal top-line and operating profit growth driven by soaring inpatient volumes and the integration of mega-acquisitions like AMRI and Sahyadri, alongside an increase in outstanding debt to fund these acquisitions (a massive portion of which will be cleared using IPO proceeds). Company has an average EPS of Rs 7.82 and average RoNW of 13.80% for the last three fiscals. Based on the pre-issue book value, the issue is priced at a Pre-Issue P/BV of 8.13x as per NAV of Rs 72.55 as on 31.03.26. Factoring in the fresh issue proceeds, the Post-Issue P/BV stands at 4.72x. If we attribute the latest earnings of FY24, FY25, and FY26 to the expanded equity base post-issue, then the asking price is at a Post-Issue P/E of around 145.68x, 71.78x, and 84.65x respectively. As per RHP, a comparison between listed peers shows the company is priced competitively in line with industry giants like Max Healthcare Institute Ltd (74.55x P/E) and Fortis Healthcare Ltd (70.22x P/E), especially when factoring in its status as India's largest network by bed capacity. On BRLM's front, Kotak Mahindra Capital Company Limited, Axis Capital Limited, Goldman Sachs (India) Securities Private Limited, Jefferies India Private Limited, J.P. Morgan India Private Limited, UBS Securities India Private Limited, and DBS Bank India Limited are associated with this IPO, and Kotak Mahindra Capital Company Limited has handled 38 IPOs in the last three fiscal years. ( As on 25.07.26 ) As per financials, Manipal Health Enterprises Limited has shown an industry-leading 29.41% revenue CAGR over the last three years, RoNW is 10.57% and the Post-Issue P/E is 145.68x, 71.78x, and 84.65x respectively as per FY24, FY25, and FY26 earnings. So the issue looks fully priced but fundamentally justified by its unmatched scale. The company is India's largest multispecialty healthcare delivery network offering products starting from basic outpatient diagnostics to highly complex quaternary care like multi-organ transplants and robotic-assisted surgeries. So, we give a NEUTRAL rating for this IPO. Readers must consult a qualified financial advisor prior to making any actual investment decisions.
✍️ Post a Comment